Guardian Pharmacy Services reported fourth‑quarter 2025 revenue of $397.6 million, up 17% year‑over‑year, driven by 12% organic growth and $20 million in incremental revenue from recent acquisitions. Adjusted earnings per share were $0.37, surpassing the consensus estimate of $0.27 and representing a 37% beat, while diluted EPS of $0.33 also exceeded expectations. Adjusted EBITDA rose 53% to $39.5 million, giving the company a 9.9% margin, an increase of 50 basis points from the 7.9% margin reported for the same quarter a year earlier.
The EPS beat was largely a result of disciplined cost control and a favorable mix shift. Management highlighted that the company’s technology‑enabled platform has delivered pricing power in assisted‑living and behavioral‑health facilities, allowing the firm to maintain margins even as it expands its resident base. The 37% beat over the $0.27 consensus reflects the combined effect of higher resident counts, stronger script volume growth, and the successful integration of acquisitions that have not yet fully diluted earnings.
Revenue growth was supported by a 10% increase in the resident count to 205,000 and a 14% rise in script volume, both of which contributed to the 17% year‑over‑year revenue increase. The $20 million incremental revenue from acquisitions, completed mid‑year, helped lift the top line and offset the integration costs that typically accompany such deals. The company’s organic revenue growth of 13% and full‑year reported revenue growth of 18% underscore the effectiveness of its expansion strategy.
Margin expansion to 9.9% was driven by higher mix and operational leverage. Gross profit rose 27% to $85.5 million, with gross margins expanding to 21.5% from 19.8% a year earlier. Adjusted EBITDA margins improved to 9.9% from 7.9% in the prior year, reflecting tighter cost controls, improved purchasing, and the impact of a more favorable product mix. These gains demonstrate the company’s ability to scale while maintaining profitability.
The company reiterated its 2026 revenue guidance of $1.400 billion to $1.420 billion, unchanged from the prior forecast, and raised its full‑year adjusted EBITDA guidance to $120 million–$124 million from $115 million–$118 million. This upgrade signals management’s confidence in continued cost discipline and margin expansion, even as it navigates the anticipated impact of the Inflation Reduction Act. The guidance reflects a measured view that the firm can sustain its 16% EBITDA growth trajectory.
"2025 was a year of broad‑based execution and disciplined investment, with results that exceeded our expectations across resident, revenue, and Adjusted EBITDA growth," said President and CEO Fred Burke. "We exited the year with strong momentum and are accordingly raising our outlook for 2026 Adjusted EBITDA in a measured manner, consistent with our philosophy of guiding to what we can clearly see." CFO David Morris added, "We ended the quarter serving over 205,000 residents, an increase of 10% year‑over‑year. Script volume grew 14% year‑over‑year, while revenue increased 17% year‑over‑year to $397.6 million, a top 12% organic growth."
The company faces headwinds from the Inflation Reduction Act, which is expected to impact drug pricing in 2026. Management expects to offset the anticipated EBITDA impact through continued cost control and purchasing optimization. Tailwinds include a growing senior population, industry consolidation, and the firm’s technology platform that enhances stickiness and pricing power across its service lines. The integration of recent acquisitions remains a short‑term margin drag, but the company’s cash generation and operational efficiency position it to manage these costs while pursuing further growth.
Guardian Pharmacy Services’ Q4 2025 results and the raised 2026 adjusted EBITDA guidance reinforce the company’s strong financial footing and its ability to sustain growth amid regulatory headwinds. The firm’s disciplined execution, technology advantage, and expanding resident base provide a solid foundation for continued performance in the long‑term care pharmacy market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.